• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Acutus Medical Inc.

    5/17/24 5:20:26 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AFIB alert in real time by email
    SC 13G 1 afib13g.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Acutus Medical, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001

    (Title of Class of Securities)

     

     

    005111109

    (CUSIP Number)

     

     

    May 9, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 810648105

     

    1.Names of Reporting Persons.

    Laurence W. Lytton

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization USA

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 1,746,823

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 1,746,823
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 1,746,823

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.9%

     

    12.Type of Reporting Person (See Instructions) IN

     

     2 
    CUSIP No. 810648105

    Item 1.

     

    (a)Name of Issuer

    Acutus Medical, Inc.

     

    (b)Address of Issuer's Principal Executive Offices

    2210 Faraday Ave., Suite 100, Carlsbad, CA

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Laurence W. Lytton

    (b)The principal business office of the Filers is located at:

    467 Central Park West
    New York, NY 10025

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to shares of Common Stock, par value $0.001of the Issuer (the "Stock").

     

    (e)The CUSIP number of the Issuer is: 005111109
     3 
    CUSIP No. 810648105
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E).

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page.

     

    The percentages reported in this Schedule 13G are based on 29,721,542 shares of Common Stock outstanding as of May 6, 2024, as reported in the Form 10-Q filed by the Issuer on May 9, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: May 17, 2024

     

     

    /s/ Laurence W. Lytton

    Laurence W. Lytton

     

     

     

    Get the next $AFIB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AFIB

    DatePrice TargetRatingAnalyst
    1/20/2022Buy → Neutral
    BTIG
    1/14/2022$10.00 → $3.00Buy → Hold
    Canaccord Genuity
    11/15/2021Neutral → Underweight
    JP Morgan
    11/12/2021Neutral → Underweight
    JP Morgan
    11/12/2021$18.00 → $10.00Buy
    Canaccord Genuity
    10/22/2021$10.00Neutral
    Goldman
    7/15/2021$11.00 → $18.00Hold → Buy
    Canaccord Genuity
    More analyst ratings

    $AFIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director by deputization Flynn James E

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      1/28/25 9:00:08 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Mukai Takeo covered exercise/tax liability with 8,475 units of Form 4, decreasing direct ownership by 10% to 72,874 units (SEC Form 4)

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      3/4/24 5:20:05 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Sohn Tom covered exercise/tax liability with 7,582 units of Form 4, decreasing direct ownership by 7% to 105,009 units (SEC Form 4)

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      2/7/24 4:12:59 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AFIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

      SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      12/16/24 9:52:56 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Acutus Medical Inc.

      SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)

      11/14/24 1:03:20 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Acutus Medical Inc.

      SC 13G - Acutus Medical, Inc. (0001522860) (Subject)

      5/17/24 5:20:26 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AFIB
    Financials

    Live finance-specific insights

    See more
    • Acutus Medical to Cancel Third Quarter 2023 Conference Call

      CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023. About Acutus Medical, Inc.Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California. Investor Contact:Chad HollisterAcutus

      11/10/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical to Announce Third Quarter 2023 Financial Results

      CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a

      11/2/23 4:13:07 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports Second Quarter 2023 Financial Results

      CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital salesQuarterly AcQMap procedure volumes set a new record and increased 21% compared to the second quarter of 2022Received FDA 510K clearance for AcQMap 9 next generation software platform featuring advanced algorithms and automation to improve diagnostic capabil

      8/7/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AFIB
    SEC Filings

    See more
    • SEC Form 10-K filed by Acutus Medical Inc.

      10-K - Acutus Medical, Inc. (0001522860) (Filer)

      3/24/25 5:27:27 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Acutus Medical, Inc. (0001522860) (Filer)

      3/24/25 4:07:31 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.

      SCHEDULE 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      1/28/25 5:40:03 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AFIB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acutus Medical Reports Full Year 2024 Financial Results

      CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024. Full Year 2024 Financial ResultsRevenue from Continuing Operations was $20.2 million for 2024, an increas

      3/24/25 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Announces Operational Downsizing

      CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, "Following an extensive strategic review by the Company's Board of Directors, we are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products." Takeo Mukai, CEO & CFO of Acutus, added, "The operational downsizing impacts our team, and it is difficult to part with our valued and highly talented colleag

      12/4/24 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results

      CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of business, a decrease of 8% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024. Thi

      11/14/24 4:26:42 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AFIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Acutus Medical downgraded by BTIG

      BTIG downgraded Acutus Medical from Buy to Neutral

      1/20/22 9:29:42 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Acutus Medical from Buy to Hold and set a new price target of $3.00 from $10.00 previously

      1/14/22 8:31:41 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical downgraded by JP Morgan

      JP Morgan downgraded Acutus Medical from Neutral to Underweight

      11/15/21 7:17:46 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $AFIB
    Leadership Updates

    Live Leadership Updates

    See more
    • Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer

      CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the fourth quarter and full year 2022. The Company also announced the appointment of Takeo Mukai as Senior Vice President & Chief Financial Officer. Preliminary Unaudited Fourth Quarter and Full Year 2022 ResultsThe Company expects fourth quarter 2022 revenue of approximately $4.7-$4.9 million compared to $4.4 million in the fourth quarter of 2021. Year-over-year growth was driven by an increase in commercial AcQMap pr

      1/9/23 6:00:00 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

      SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

      9/7/22 8:30:00 AM ET
      $AFIB
      $AVGR
      $HYPR
      $NUVA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Acutus Medical Appoints Niamh Pellegrini to Board of Directors

      CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021. Ms. Pellegrini has over 20 years of experience in the healthcare industry and, since July 2019, has served as the Chief Commercial Officer of Nevro, Inc., a medical device company dedicated to helping patients suffering from chronic pain achieve lasting relief. "Niamh is an experienced and proven executive and commercial leader," said Vince Burgess, President and CEO of Acutu

      8/12/21 4:02:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care